Driving innovation through effective financing and deal-making strategies continues to be an imperative for companies in the biotechnology industry. Continued public scrutiny of drug pricing, heightened expectations of payers regarding a drug’s value and regulatory and policy risks all have a significant impact on investor sentiment on the sector, its growth prospects and company valuation.
This panel will bring together leaders from life sciences and venture capital firms to analyze the sentiments of investors towards the sector in 2018 and evaluate trends in deal-making in the context of the rising expectations of the investors, payers and other stakeholders. These expectations in turn require companies to access new capabilities and adjust development and commercial strategies. The discussion will be guided by financial data and industry findings at EY.

Ability Level: Intermediate

Session ID: 21122